Skip to main content

Oscient Pharmaceuticals


rocketed more than 36% on news that it will pay lower royalties in connection with its Factive antibiotic product license to LG Life Sciences, and that LG is now authorized to sell Factive in all current member countries of the European Union -- more than 40 in total. Shares of the Massachusetts-based company were trading up $1.52, to $5.72, in recent trading.

Keithley Instruments

( KEI) rose after the electronics-parts maker found no evidence of stock-options backdating in its internal investigation of the company's options grant practices. The Ohio-based company says that, from 2000 through 2002, days-long delays between initial board approval of grants, and ultimate recording of the grants, resulted in lower exercise prices than the stock price on board approval dates. It didn't, however, find "intentional misconduct" in these actions, and it won't need to restate any results. Shares were gaining 60 cents, or 4.7%, to $13.46.

Spirent Communications

( SPM) fell after the Britain-based company announced Edward Bramson as its new board chairman. Shares were slipping 12 cents, or 2.6% to $4.45.

Royal Gold


dropped after the Denver-based mine-management company paid $100 million in cash and stock for a 2% net smelter return royalty on


Scroll to Continue

TheStreet Recommends


Penasquito project in Zacatecas, Mexico, which contains large reserves of silver, gold, zinc and lead. It also bought the rights to royalties on several other nearby properties, ranging from 1% to 2%, which will expire on May 1. The Penasquito transaction will likely close in early 2007. Shares were losing 82 cents, or 2.2%, to $36.22.

Savient Pharmaceuticals


announced that the Federal Circuit Court of Appeals had denied its motion for a preliminary injunction against

Novartis Pharmaceuticals


subsidiary Sandoz Pharma and Upsher-Smith Laboratories, in connection with its patent infringement suit against the companies.

The court has only temporarily blocked sale of Sandoz and Upsher-Smith's generic oxandrolone, which Savient says infringes on its Oxandrin drug, while it reviews the case. Meanwhile, Savient has launched its own authorized version of generic oxandrolone, which treats involuntary weight loss. The drug will be manufactured and supplied through Savient and distributed by

Watson Pharmaceuticals


. But shares retreated 47 cents, or 3.9%, to $11.54.